Global Platelet-Derived Growth Factor Receptor Inhibitors Market Growth (Status and Outlook) 2024-2030
Description
Global Platelet-Derived Growth Factor Receptor Inhibitors Market Growth (Status and Outlook) 2024-2030
The FDA has approved more than 10 PDGFR multikinase antagonists for the treatment of various tumor diseases and pulmonary fibrosis. Recombinant PDGF is used to help treat chronic ulcers, orthopedic surgery and periodontal disease to stimulate bone regeneration and repair. When PDGF is used alone or in combination with other growth factors to stimulate soft and hard tissue healing.
The global Platelet-Derived Growth Factor Receptor Inhibitors market size is projected to grow from US$ 2424 million in 2024 to US$ 3735 million in 2030; it is expected to grow at a CAGR of 7.5% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Platelet-Derived Growth Factor Receptor Inhibitors Industry Forecast” looks at past sales and reviews total world Platelet-Derived Growth Factor Receptor Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Platelet-Derived Growth Factor Receptor Inhibitors sales for 2023 through 2029. With Platelet-Derived Growth Factor Receptor Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Platelet-Derived Growth Factor Receptor Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Platelet-Derived Growth Factor Receptor Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Platelet-Derived Growth Factor Receptor Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Platelet-Derived Growth Factor Receptor Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Platelet-Derived Growth Factor Receptor Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Platelet-Derived Growth Factor Receptor Inhibitors.
United States market for Platelet-Derived Growth Factor Receptor Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Platelet-Derived Growth Factor Receptor Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Platelet-Derived Growth Factor Receptor Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Platelet-Derived Growth Factor Receptor Inhibitors players cover Novartis, Eli Lilly, Eisai, Pfizer, GSK, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Platelet-Derived Growth Factor Receptor Inhibitors market by product type, application, key players and key regions and countries.
Segmentation by Type:
Capsules
Tablets
Others
Segmentation by Application:
Hospitals
Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Capsules
Tablets
Others
Segmentation by Application:
Hospitals
Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Eli Lilly
Eisai
Pfizer
GSK
Boehringer Ingelheim
Il-Yang Pharmaceutical
Takeda
Bayer
Bristol-Myers Squibb
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
87 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size 2019-2030
- 2.1.2 Platelet-Derived Growth Factor Receptor Inhibitors Market Size CAGR by Region (2019 VS 2023 VS 2030)
- 2.1.3 World Current & Future Analysis for Platelet-Derived Growth Factor Receptor Inhibitors by Country/Region, 2019, 2023 & 2030
- 2.2 Platelet-Derived Growth Factor Receptor Inhibitors Segment by Type
- 2.2.1 Capsules
- 2.2.2 Tablets
- 2.2.3 Others
- 2.3 Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Type
- 2.3.1 Platelet-Derived Growth Factor Receptor Inhibitors Market Size CAGR by Type (2019 VS 2023 VS 2030)
- 2.3.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Market Share by Type (2019-2024)
- 2.4 Platelet-Derived Growth Factor Receptor Inhibitors Segment by Application
- 2.4.1 Hospitals
- 2.4.2 Clinics
- 2.5 Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Application
- 2.5.1 Platelet-Derived Growth Factor Receptor Inhibitors Market Size CAGR by Application (2019 VS 2023 VS 2030)
- 2.5.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Size Market Share by Application (2019-2024)
- 3 Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Player
- 3.1 Platelet-Derived Growth Factor Receptor Inhibitors Market Size Market Share by Player
- 3.1.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue by Player (2019-2024)
- 3.1.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Revenue Market Share by Player (2019-2024)
- 3.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
- 4 Platelet-Derived Growth Factor Receptor Inhibitors by Region
- 4.1 Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Region (2019-2024)
- 4.2 Global Platelet-Derived Growth Factor Receptor Inhibitors Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth (2019-2024)
- 4.4 APAC Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth (2019-2024)
- 4.5 Europe Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth (2019-2024)
- 4.6 Middle East & Africa Platelet-Derived Growth Factor Receptor Inhibitors Market Size Growth (2019-2024)
- 5 Americas
- 5.1 Americas Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Country (2019-2024)
- 5.2 Americas Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Type (2019-2024)
- 5.3 Americas Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Region (2019-2024)
- 6.2 APAC Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Type (2019-2024)
- 6.3 APAC Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 7 Europe
- 7.1 Europe Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Country (2019-2024)
- 7.2 Europe Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Type (2019-2024)
- 7.3 Europe Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Platelet-Derived Growth Factor Receptor Inhibitors by Region (2019-2024)
- 8.2 Middle East & Africa Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Type (2019-2024)
- 8.3 Middle East & Africa Platelet-Derived Growth Factor Receptor Inhibitors Market Size by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Global Platelet-Derived Growth Factor Receptor Inhibitors Market Forecast
- 10.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Forecast by Region (2025-2030)
- 10.1.1 Global Platelet-Derived Growth Factor Receptor Inhibitors Forecast by Region (2025-2030)
- 10.1.2 Americas Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.1.3 APAC Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.1.4 Europe Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.1.5 Middle East & Africa Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.2 Americas Platelet-Derived Growth Factor Receptor Inhibitors Forecast by Country (2025-2030)
- 10.2.1 United States Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.2.2 Canada Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.2.3 Mexico Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.2.4 Brazil Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.3 APAC Platelet-Derived Growth Factor Receptor Inhibitors Forecast by Region (2025-2030)
- 10.3.1 China Platelet-Derived Growth Factor Receptor Inhibitors Market Forecast
- 10.3.2 Japan Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.3.3 Korea Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.3.4 Southeast Asia Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.3.5 India Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.3.6 Australia Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.4 Europe Platelet-Derived Growth Factor Receptor Inhibitors Forecast by Country (2025-2030)
- 10.4.1 Germany Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.4.2 France Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.4.3 UK Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.4.4 Italy Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.4.5 Russia Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.5 Middle East & Africa Platelet-Derived Growth Factor Receptor Inhibitors Forecast by Region (2025-2030)
- 10.5.1 Egypt Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.5.2 South Africa Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.5.3 Israel Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.5.4 Turkey Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 10.6 Global Platelet-Derived Growth Factor Receptor Inhibitors Forecast by Type (2025-2030)
- 10.7 Global Platelet-Derived Growth Factor Receptor Inhibitors Forecast by Application (2025-2030)
- 10.7.1 GCC Countries Market Platelet-Derived Growth Factor Receptor Inhibitors Forecast
- 11 Key Players Analysis
- 11.1 Novartis
- 11.1.1 Novartis Company Information
- 11.1.2 Novartis Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.1.3 Novartis Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.1.4 Novartis Main Business Overview
- 11.1.5 Novartis Latest Developments
- 11.2 Eli Lilly
- 11.2.1 Eli Lilly Company Information
- 11.2.2 Eli Lilly Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.2.3 Eli Lilly Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.2.4 Eli Lilly Main Business Overview
- 11.2.5 Eli Lilly Latest Developments
- 11.3 Eisai
- 11.3.1 Eisai Company Information
- 11.3.2 Eisai Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.3.3 Eisai Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.3.4 Eisai Main Business Overview
- 11.3.5 Eisai Latest Developments
- 11.4 Pfizer
- 11.4.1 Pfizer Company Information
- 11.4.2 Pfizer Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.4.3 Pfizer Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.4.4 Pfizer Main Business Overview
- 11.4.5 Pfizer Latest Developments
- 11.5 GSK
- 11.5.1 GSK Company Information
- 11.5.2 GSK Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.5.3 GSK Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.5.4 GSK Main Business Overview
- 11.5.5 GSK Latest Developments
- 11.6 Boehringer Ingelheim
- 11.6.1 Boehringer Ingelheim Company Information
- 11.6.2 Boehringer Ingelheim Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.6.3 Boehringer Ingelheim Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.6.4 Boehringer Ingelheim Main Business Overview
- 11.6.5 Boehringer Ingelheim Latest Developments
- 11.7 Il-Yang Pharmaceutical
- 11.7.1 Il-Yang Pharmaceutical Company Information
- 11.7.2 Il-Yang Pharmaceutical Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.7.3 Il-Yang Pharmaceutical Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.7.4 Il-Yang Pharmaceutical Main Business Overview
- 11.7.5 Il-Yang Pharmaceutical Latest Developments
- 11.8 Takeda
- 11.8.1 Takeda Company Information
- 11.8.2 Takeda Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.8.3 Takeda Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.8.4 Takeda Main Business Overview
- 11.8.5 Takeda Latest Developments
- 11.9 Bayer
- 11.9.1 Bayer Company Information
- 11.9.2 Bayer Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.9.3 Bayer Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.9.4 Bayer Main Business Overview
- 11.9.5 Bayer Latest Developments
- 11.10 Bristol-Myers Squibb
- 11.10.1 Bristol-Myers Squibb Company Information
- 11.10.2 Bristol-Myers Squibb Platelet-Derived Growth Factor Receptor Inhibitors Product Offered
- 11.10.3 Bristol-Myers Squibb Platelet-Derived Growth Factor Receptor Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
- 11.10.4 Bristol-Myers Squibb Main Business Overview
- 11.10.5 Bristol-Myers Squibb Latest Developments
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
